The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kogan E.A.

Sechenov First Moscow State Medical University

Saltykov B.B.

Sechenov First Moscow State Medical University

Atanov P.V.

Sechenov First Moscow State Medical University

Primary generalized AL amyloidosis

Authors:

Kogan E.A., Saltykov B.B., Atanov P.V.

More about the authors

Read: 4102 times


To cite this article:

Kogan EA, Saltykov BB, Atanov PV. Primary generalized AL amyloidosis. Russian Journal of Archive of Pathology. 2021;83(1):31‑34. (In Russ.)
https://doi.org/10.17116/patol20218301131

Recommended articles:
Cardiac myxoma: biological features, morphology, differential diagnosis. Russian Journal of Archive of Pathology. 2024;(6):74-81
Soli­tary fibrous tumor of the kidney. Russian Journal of Archive of Pathology. 2025;(3):77-81
Scanning electron microscopy in hemo­tology. Labo­ratory Service. 2025;(1):38-47

References:

  1. Pal’tsev MA, Kakturskii LV, Zairat’yants OV, eds. Patologicheskaya anatomiya. Natsional’noe rukovodstvo. M.: GEOTAR-Media; 2011. (In Russ.).
  2. Guo YM, Takahashi N, Miyabe K, Yoshida M, Abe F, Yamashita T, Nara M, Yoshioka T, Ohashi K, Goto A, Takahashi N. Immunoglobulin light chain amyloidosiswith severe liver dysfunction accompanied by factor X deficiency. Intern Med. 2019;58(20):3039-3043. https://doi.org/10.2169/internalmedicine.2864-19
  3. Tret’yakov AYu, Zakharchenko SP, Tret’yakova VA, Ermilov OV, Shekhovtsov SA, Khabibulin RR, Aleinikova KS, Dan VS, Leshcheva NA. Clinical observation of a combination of diffuse alveololar-septal pulmonary lesion and amyloid cardiomyopathy in systemic AL-amiloidosis in the elderly. Terapevticheskii arkhiv. 2018;90(12):96-100. (In Russ.).
  4. Varga C, Titus SE, Toskic D, Comenzo RL. Use of novel therapies in the treatment of light chain amyloidosis. Blood Rev. 2019;37:100581.
  5. Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y. Human amyloidosis still intractable but becoming curable: The essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int. 2020;70(4):191-198. 
  6. Paukov VS, ed. Klinicheskaya patologiya. Rukovodstvo dlya vrachey. M.: Litterra; 2018. (In Russ.).
  7. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, et al. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid. 2019;26(suppl 1):101-102.  ttps://doi.org/10.1080/13506129.2019.1582486
  8. D’Souza A, Magnus BE, Myers J, Dispenzieri A, Flynn KE. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid. 2020;27(2):111-118.  https://doi.org/10.1080/13506129.2020.1713743

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.